Olink Platform-Based Identification of Peripheral Blood Biomarkers for irAEs in Advanced NSCLC.
6 affiliations
- 1Department of Pulmonary and Critical Care Medicine, Peking University Shenzhen Hospital, Shenzhen 518036, China.
- 2Department of Pulmonary and Critical Care Medicine, Targeted Tracer Research and Development Laboratory, Frontiers Science Center for Disease-Related Molecular Network, State Key Laboratory of Respiratory Health and Multimorbidity, West China Hospital, West China School of Medicine, Sichuan University, Chengdu 610041, China.
- 3PKU-Shenzhen Clinical Institute, Shantou University Medical College, Shenzhen 518000, China.
- 4Department of Radiotherapy Oncology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 528406, China.
- 5Department of Radiation Oncology, Sichuan Cancer Hospital and Institute, University of Electronic Science and Technology of China, Chengdu 610041, China.
- 6Health Science Center, Shenzhen University, Shenzhen 518060, China.
Abstract
Lung cancer is the leading cause of cancer-related mortality worldwide. Immunotherapy has transformed the treatment landscape for advanced non-small cell lung cancer (NSCLC). However, immune-related adverse events (irAEs) represent a major clinical challenge during immunotherapy. These events can affect any organ system, and severe irAEs may necessitate treatment interruption or lead to life-threatening outcomes. We prospectively enrolled 84 advanced NSCLC patients treated with immunotherapy (June 2022-June 2024, followed until February 2025), including 57 who developed grade 1-4 irAEs and 27 who did not. Peripheral blood was collected from 39 patients at baseline for Olink platform-based proteomic screening, complemented by flow cytometric analysis of lymphocyte subsets. Olink profiling revealed IL13 and TRAIL as the most significantly differentially expressed proteins between irAEs and non-irAE groups. These proteins were enriched in biological processes such as negative regulation of lung ciliated cell differentiation and positive regulation of lung goblet cell differentiation, as well as in asthma and inflammatory bowel disease pathways. Moreover, dynamic changes in total T lymphocytes, T helper cells, NK cells, and the CD4/CD8 ratio were strongly associated with irAE occurrence. These markers, readily measurable in peripheral blood, offer potential for early risk stratification and real-time monitoring.
Related
- Exploration of plasma proteomic landscapes using Olink Reveal technology to identify biomarkers for early-stage/localized gastric cancer.
- Maximizing cardiopulmonary support as a minimally invasive platform—using peripheral parallel veno-venous and veno-arterial extracorporeal membrane oxygenation and axillary impella 5.5 as a bridge to heart–lung transplantation
- A Preliminary Exploratory Study Based on LC–MS/MS and LFQ for Candidate Protein Biomarkers in Peripheral Blood from Rheumatoid Arthritis
- A Systems Biology Model Linking Peripheral NIMETOX Biomarkers to Multilevel Brain Structural and Functional Alterations Across Major Depression and Schizophrenia
- SPLASH: a benchtop platform for accessible, ultrasensitive quantification of plasma biomarkers in Alzheimer’s disease
BibTeX
@article{zhang2026olink,
title = {{Olink Platform-Based Identification of Peripheral Blood Biomarkers for irAEs in Advanced NSCLC.}},
author = {Zhihan Zhang and Bingchun Chen and Hanmei Jiang and Ziyan Zhang and Jianming Mo and Yanyi Hou and Shuang Liu and Ping Xu},
journal = {Current oncology (Toronto, Ont.)},
year = {2026},
month = oct,
doi = {10.3390/curroncol33100605},
url = {https://europepmc.org/article/MED/42930174},
note = {CC BY},
}
RIS
TY - JOUR
TI - Olink Platform-Based Identification of Peripheral Blood Biomarkers for irAEs in Advanced NSCLC.
AU - Zhihan Zhang
AU - Bingchun Chen
AU - Hanmei Jiang
AU - Ziyan Zhang
AU - Jianming Mo
AU - Yanyi Hou
AU - Shuang Liu
AU - Ping Xu
PY - 2026
DA - 2026/10/09
JO - Current oncology (Toronto, Ont.)
DO - 10.3390/curroncol33100605
UR - https://europepmc.org/article/MED/42930174
AB - Lung cancer is the leading cause of cancer-related mortality worldwide. Immunotherapy has transformed the treatment landscape for advanced non-small cell lung cancer (NSCLC). However, immune-related adverse events (irAEs) represent a major clinical challenge during immunotherapy. These events can affect any organ system, and severe irAEs may necessitate treatment interruption or lead to life-threatening outcomes. We prospectively enrolled 84 advanced NSCLC patients treated with immunotherapy (June 2022-June 2024, followed until February 2025), including 57 who developed grade 1-4 irAEs and 27 who did not. Peripheral blood was collected from 39 patients at baseline for Olink platform-based proteomic screening, complemented by flow cytometric analysis of lymphocyte subsets. Olink profiling revealed IL13 and TRAIL as the most significantly differentially expressed proteins between irAEs and non-irAE groups. These proteins were enriched in biological processes such as negative regulation of lung ciliated cell differentiation and positive regulation of lung goblet cell differentiation, as well as in asthma and inflammatory bowel disease pathways. Moreover, dynamic changes in total T lymphocytes, T helper cells, NK cells, and the CD4/CD8 ratio were strongly associated with irAE occurrence. These markers, readily measurable in peripheral blood, offer potential for early risk stratification and real-time monitoring.
SN - 1198-0052
SN - 1718-7729
ER -